BlackRock, Inc. 13D and 13G filings for Edgewise Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-17 7:54 pm Sale | 2025-06-30 | 13G | Edgewise Therapeutics, Inc. EWTX | BlackRock Inc. BLK | 5,824,866 5.500% | -568,701 (-8.89%) | Filing |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX | BlackRock Inc. BLK | 6,393,567 6.800% | 0 (Unchanged) | Filing |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX | BlackRock Inc. BLK | 6,393,567 6.800% | 2,888,368 (+82.40%) | Filing |
| 2024-02-07 5:09 pm Purchase | 2024-01-31 | 13G | Edgewise Therapeutics, Inc. EWTX | BlackRock Inc. BLK | 3,505,199 4.100% | 198,089 (+5.99%) | Filing |
| 2024-02-02 3:57 pm Purchase | 2023-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX | BlackRock Inc. BLK | 3,307,110 5.200% | 3,307,110 (New Position) | Filing |